Hugel, a leading global medical aesthetics company, announced record-breaking net sales and operating profit for the third quarter of 2024. The company’s strong performance was driven by its global expansion, particularly the initial shipment of its botulinum toxin product to the US market. Hugel is poised for further growth, with plans to expand its presence in the US and other key markets.